The Epithelial Biomedicine division investigates in the field of skin regenerative medicine, mainly in the study of a rare skin disease called Epidermolysis Bullosa. The division is involved in numerous clinical and pre-clinical initiatives that include both the study of the mechanisms involved in the pathology, as well as the development of new efficient therapeutic approaches, based on both pharmacological therapies and new advanced therapies.

Among the therapies developed, the development of two clinical protocols to test the efficacy of mesenchymal stromal cells in the treatment of ulcers and chronic wounds in patients with Dystrophic Epidermolysis Bullosa or the development of a bioengineered skin substitute for the treatment of skin loss, such as third degree burns.

For more information, consult the Epithelial Biomedicine division website.